Warfarin

Generic Name
Warfarin
Brand Names
Coumadin, Jantoven
Drug Type
Small Molecule
Chemical Formula
C19H16O4
CAS Number
81-81-2
Unique Ingredient Identifier
5Q7ZVV76EI
Background

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.

Indication

Indicated for:

1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.

2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.

3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.

4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction.

Off-label uses include:

1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.

Associated Conditions
Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)
Associated Therapies
-

Cost Effectiveness Analysis In Patients With Heart Valve Prosthesis

First Posted Date
2013-12-27
Last Posted Date
2013-12-30
Lead Sponsor
Pharmacoeconomic Unit, Egypt
Target Recruit Count
300
Registration Number
NCT02022527
Locations
🇪🇬

Ain Shams University hospitals, Cairo, Egypt

Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects

First Posted Date
2013-12-27
Last Posted Date
2017-04-04
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
24
Registration Number
NCT02022254
Locations
🇩🇪

Novo Nordisk Investigational Site, Berlin, Germany

Drug-drug Interaction Study(Lobeglitazone, Warfarin)

Phase 1
Completed
Conditions
Interventions
First Posted Date
2013-12-06
Last Posted Date
2014-07-03
Lead Sponsor
Chong Kun Dang Pharmaceutical
Target Recruit Count
24
Registration Number
NCT02002611
Locations
🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

D-Dimer Determined Anticoagulation INTENSITY in Patients With Mechanical Valve Replacement

Completed
Conditions
Interventions
First Posted Date
2013-11-27
Last Posted Date
2017-06-26
Lead Sponsor
Wuhan Asia Heart Hospital
Target Recruit Count
772
Registration Number
NCT01996657
Locations
🇨🇳

Wuhan Asia Heart Hospital, Wuhan, Hubei, China

🇨🇳

WAHH, Wuhan, Hubei, China

Short Term Warfarin Therapy for Radiofrequency Catheter Ablation of Atrial Fibrillation

Not Applicable
Conditions
Interventions
First Posted Date
2013-11-25
Last Posted Date
2013-11-25
Lead Sponsor
Korea University Anam Hospital
Target Recruit Count
520
Registration Number
NCT01991951
Locations
🇰🇷

Korea University Anam Hospital, Seoul, Korea, Republic of

Cognitive Impairment Related to Atrial Fibrillation Prevention Trial

Phase 4
Completed
Conditions
Interventions
First Posted Date
2013-11-25
Last Posted Date
2021-09-29
Lead Sponsor
University of Sao Paulo
Target Recruit Count
200
Registration Number
NCT01994265
Locations
🇧🇷

Federal Univeristy of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil

🇧🇷

Heart Institute - University of São Paulo, São Paulo, Brazil

Prevention of Recurrence After Thrombolysis in Acute Iliofemoral Venous Thrombosis (PRAIS) Study

First Posted Date
2013-11-18
Last Posted Date
2014-11-19
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
72
Registration Number
NCT01986192
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates

First Posted Date
2013-07-30
Last Posted Date
2017-06-26
Lead Sponsor
Astellas Pharma Europe B.V.
Target Recruit Count
14
Registration Number
NCT01911728
Locations
🇿🇦

Parexel, George, South Africa

🇿🇦

Parexel/Qdot Pharma, Port Elizabeth, South Africa

Dabigatran Versus Warfarin After Mitral and/or Aortic Bioprosthesis Replacement and Atrial Fibrillation Postoperatively

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2013-06-04
Last Posted Date
2015-10-09
Lead Sponsor
Hospital Ana Nery
Target Recruit Count
27
Registration Number
NCT01868243
Locations
🇧🇷

Hospital Ana Nery, Salvador, Bahia, Brazil

© Copyright 2024. All Rights Reserved by MedPath